相关实验视频
Updated: Jan 9, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
达里埃病成功用托法西提尼布治疗:一个病例报告
Elham Behrangi1, Abbas Dehghani1, Roya Zeinali1
1Department of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
简氏激酶 (JAK) 抑制剂对治疗达里尔病 (DD) 是一种罕见的遗传性皮肤疾病有前途. 一名耐火DD患者经历了JAK抑制剂托法西替尼的显著症状改善.
科学领域:
- 皮肤病学 皮肤病学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 达里尔病 (DD) 是一种罕见的,遗传性皮肤疾病,导致显著的发病率.
- 目前对DD的治疗方法有限,目前还没有确定的治疗方法.
- 简氏激酶 (JAK) 抑制剂正在成为治疗难以治疗的皮肤病的潜在疗法.
研究的目的:
- 报告一个用JAK抑制剂治疗的耐火达里尔病病例.
- 评估托法西提尼布在治疗严重DD症状方面的疗效和安全性.
主要方法:
- 一名42岁的女性患者接受了治疗,她的活检证实了达里尔病.
- 最初的阿达利穆马布治疗无效.
- 随后,患者接受了托法西提尼布治疗,根据反应调整剂量.
主要成果:
- 托法西替尼治疗导致每天10毫克的疾病稳定.
- 将剂量提高到每天15毫克,导致病变和的显著改善.
- 每天10毫克的维持剂量成功控制了病变的病变解决.
结论:
- 简氏激酶 (JAK) 抑制剂,特别是托法西提尼布,代表了耐火达利尔病的潜在治疗选择.
- 这一案例表明,JAK抑制可以有效地管理严重的DD症状,为治疗选择有限的患者提供希望.
更多相关视频
11:34A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
08:43Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...